Related Experiment Video
Updated: Mar 29, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.8K
Genetic polymorphisms in COL18A1 influence the development of osteosarcoma
Zhihao Guo1, Tianji Zhang1, Juntao Wu1
1Department of Orthopedics, The Third Affiliated Hospital of Xinxiang Medical University Xinxiang, China.
International Journal of Clinical and Experimental Pathology
|December 1, 2015
Summary
The collagen type XVIII alpha 1 chain (COL18A1) D104N polymorphism is linked to osteosarcoma risk in Chinese individuals. Specifically, the NN genotype significantly increases osteosarcoma development risk.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Osteosarcoma is a primary bone malignancy with complex etiology.
- Genetic factors, including single nucleotide polymorphisms (SNPs), are implicated in osteosarcoma development.
- The COL18A1 gene encodes a component of the extracellular matrix, potentially influencing tumor behavior.
Purpose of the Study:
- To investigate the association between the COL18A1 D104N polymorphism and osteosarcoma risk.
- To analyze the impact of different COL18A1 D104N genotypes on osteosarcoma susceptibility in a Chinese population.
Main Methods:
- A case-control study design was employed.
- 141 osteosarcoma patients and 341 controls were recruited.
- Genotyping of the COL18A1 D104N polymorphism was performed using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).
- Logistic regression analysis was used to assess risk associations.
Main Results:
- Individuals with the NN genotype of COL18A1 D104N showed a significantly increased risk of osteosarcoma compared to the DD genotype (OR=20.97).
- In a dominant model, the NN+DN genotype conferred a 1.99-fold increased risk.
- In a recessive model, the NN genotype was associated with a 20.45-fold increased risk.
- No significant interactions were found between the polymorphism and clinical factors like Enneking stage or tumor metastasis.
Conclusions:
- The homozygous DN and NN genotypes of the COL18A1 D104N polymorphism are associated with an increased risk of osteosarcoma.
- This genetic variation may play a role in osteosarcoma susceptibility within the studied population.
- Further research is warranted to elucidate the functional mechanisms underlying this association.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
118
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
118
01:33Pleiotropy
44.0K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
44.0K
01:27Principles of Pharmacogenetics: Types of Genetic Variants
95
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76